Log in

Relevant bibliographies by topics / Lactation – Drug effects

Contents

Journal articles
Books
Book chapters

Academic literature on the topic 'Lactation – Drug effects'

Author: Grafiati

Published: 4 June 2021

Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Lactation – Drug effects.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Lactation – Drug effects"

1

Frey, Bruce M., and James O'Donnell. "Drug Therapy in Pregnancy and Lactation." Journal of Pharmacy Practice 2, no. 1 (February 1989): 2–12. http://dx.doi.org/10.1177/089719008900200102.

Full text

Abstract:

The use of drugs in pregnant and lactating women requires a thorough understanding of the unique interactions between the mother, fetus/infant, and the pharmacologic agents that are used in therapy. Any agent that is consumed by a woman may have adverse effects on the fetus/infant. This article will summarize those factors that should be considered. There exists a paucity of data and information for most drugs relative to pregnancy and lactation. Conclusions that can be drawn remain speculative, and the use of any drug during pregnancy and lactation requires extreme caution. Factors involved in fetal drug exposure include the dynamic changes of maternal physiology related to drug absorption, distribution, metabolism, and excretion. Placental transfer of drug occurs with almost all agents, each to varying degrees. The notion that the placenta provides an impervious barrier must be dismissed. The least understood of factors involving potential fetal harm is teratogenicity. The mechanisms and types of teratogenic agents, poorly understood in humans, is discussed. Most drugs appear in the breast milk and, therefore, carry some degree of potential harm. Minimizing exposure is a goal that can be obtained when taking into account the maternal physiology, basic pharmacokinetic factors, physiochemical interactions between drug and membranes, and the chemical composition of breast milk.

APA, Harvard, Vancouver, ISO, and other styles

2

Walson, Philip D. "Drug Exposure and Effects in Pregnancy and Lactation." Therapeutic Drug Monitoring 42, no. 2 (April 2020): 169–71. http://dx.doi.org/10.1097/ftd.0000000000000732.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Ahirwar, Sakshi, Saloni Chourasia, and Bhagyashree Mahajan. "Drugs Used During Pregnancy and Lactation." International Journal of Pharmaceutical Sciences and Medicine 6, no. 8 (August 30, 2021): 78–103. http://dx.doi.org/10.47760/ijpsm.2021.v06i08.006.

Full text

Abstract:

In time of pregnancy, drugs are often required to treat certain disorders. In general potential benefit outweighs known risks, drugs may be considered for treatment of disorders during pregnancy. All maternal drugs not cross the planceta to the fetus. Some drugs that cross the placenta may have a direct toxic effect or teratogenic effect . Understanding the risks of drugs use in pregnancy has lagged being the advances in other areas of pharmacotherapy. The adverse developmental effects of pharmaceutical products are recognized to include not only mal formation, but also growth restrictions, fetal death and functional defects in the newborn. Drug that does not cross placenta but still harm the fortus. 1979, FDA developed a system determining teratogenic risk of drugs based on animals& human studies. Divided drugs into 5 categories (A ,B, C, D, X). This article provide clinical therapeutic guidance relating drug use in pregnancy.

APA, Harvard, Vancouver, ISO, and other styles

4

Anderson, Philip O. "Drug Therapy for Weight Loss: Effects on Lactation and Breastfeeding." Breastfeeding Medicine 15, no. 5 (May 1, 2020): 294–96. http://dx.doi.org/10.1089/bfm.2020.0023.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Bond, G. M., and A. M. Holloway. "Anaesthesia and Breast-feeding – the Effect on Mother and Infant." Anaesthesia and Intensive Care 20, no. 4 (November 1992): 426–30. http://dx.doi.org/10.1177/0310057x9202000404.

Full text

Abstract:

In this paper, we summarise the physiology of lactation and discuss the pathophysiology brought about by fasting, stress and anaesthetic drugs. Drug secretion into breast milk and subsequent absorption by the infant is considered. Maternal hydration must be well maintained with intravenous fluids, allowing an added 500 to 1000 ml for daily fluid loss in lactation. Maternal premedication, general anaesthesia and routine postoperative analgesics are also discussed as to the effects on the breast-fed infant. Drug side-effects may be avoided by timing breast feeding just before the next due dose. Sedatives with long half-lives should not be used. Endocrine and metabolic responses to anaesthesia and surgery are less with regional anaesthesia than with general, hence regional anaesthesia is preferred where it is a reasonable alternative technique.

APA, Harvard, Vancouver, ISO, and other styles

6

Jügens, TP, C. Schaefer, and A. May. "Treatment of Cluster Headache in Pregnancy and Lactation." Cephalalgia 29, no. 4 (April 2009): 391–400. http://dx.doi.org/10.1111/j.1468-2982.2008.01764.x.

Full text

Abstract:

Cluster headache is a rare disorder in women, but has a serious impact on the affected woman's life, especially on family planning. Women with cluster headache who are pregnant need special support, including the expertise of an experienced headache centre, an experienced gynaecologist and possibly a teratology information centre. The patient should be seen through all stages of the pregnancy. A detailed briefing about the risks and safety of various treatment options is mandatory. In general, both the number of medications and the dosage should be kept as low as possible. Preferred treatments include oxygen, subcutaneous or intranasal sumatriptan for acute pain and verapamil and prednisone/ prednisolone as preventatives. If there is a compelling reason to treat the patient with another preventative, gabapentin is the drug of choice. While breastfeeding, oxygen, sumatriptan and lidocaine for acute pain and prednisone/prednisolone, verapamil, and lithium as preventatives are the drugs of choice. As the individual pharmacokinetics differ substantially, adverse drug effects should be considered if unexplained symptoms occur in the newborn.

APA, Harvard, Vancouver, ISO, and other styles

7

Griffin, Brooke L., Rebecca H. Stone, Shareen Y. El-Ibiary, Sarah Westberg, Kayce Shealy, Alicia Forinash, Abigail Yancey, et al. "Guide for Drug Selection During Pregnancy and Lactation: What Pharmacists Need to Know for Current Practice." Annals of Pharmacotherapy 52, no. 8 (March 9, 2018): 810–18. http://dx.doi.org/10.1177/1060028018764447.

Full text

Abstract:

Objective: To provide guidance for clinicians on risk assessment of medication use during pregnancy and lactation. Data Sources: Authors completed PubMed searches to identify articles focused on the use of medications in pregnancy, including fetal development, drug transfer across the placenta, trimester exposure, chronic conditions in pregnancy, medications in lactation, and lactation and chronic disease. Study Selection and Data Extraction: Articles were reviewed to provide overall guidance to medication selection during pregnancy. The following information was reviewed: medication use in pregnancy, including fetal development, drug transfer across the placenta, trimester exposure, chronic conditions in pregnancy, medications in lactation, and lactation and chronic disease. Data Synthesis: This article will provide an overview of medication safety considerations during pregnancy and lactation. Information was interpreted to help clinicians predict the potential risk and benefit in each patient to make an evidence-based decision. The article concludes with guidance on risk assessment and how pharmacists may support fellow health care providers and their patients when considering medication use. Conclusions: Information about the effects of medication use during reproductive periods is limited. With the removal of the Food and Drug Administration pregnancy categories, clinicians will be relying on pharmacists to aid in the appropriate selection of therapies for patients. It is critical that pharmacists keep abreast of resources available and be able to assess data to help prescribers and their patients.

APA, Harvard, Vancouver, ISO, and other styles

8

García-Lino, Álvarez-Fernández, Blanco-Paniagua, Merino, and Álvarez. "Transporters in the Mammary Gland—Contribution to Presence of Nutrients and Drugs into Milk." Nutrients 11, no. 10 (October 5, 2019): 2372. http://dx.doi.org/10.3390/nu11102372.

Full text

Abstract:

A large number of nutrients and bioactive ingredients found in milk play an important role in the nourishment of breast-fed infants and dairy consumers. Some of these ingredients include physiologically relevant compounds such as vitamins, peptides, neuroactive compounds and hormones. Conversely, milk may contain substances—drugs, pesticides, carcinogens, environmental pollutants—which have undesirable effects on health. The transfer of these compounds into milk is unavoidably linked to the function of transport proteins. Expression of transporters belonging to the ATP-binding cassette (ABC-) and Solute Carrier (SLC-) superfamilies varies with the lactation stages of the mammary gland. In particular, Organic Anion Transporting Polypeptides 1A2 (OATP1A2) and 2B1 (OATP2B1), Organic Cation Transporter 1 (OCT1), Novel Organic Cation Transporter 1 (OCTN1), Concentrative Nucleoside Transporters 1, 2 and 3 (CNT1, CNT2 and CNT3), Peptide Transporter 2 (PEPT2), Sodium-dependent Vitamin C Transporter 2 (SVCT2), Multidrug Resistance-associated Protein 5 (ABCC5) and Breast Cancer Resistance Protein (ABCG2) are highly induced during lactation. This review will focus on these transporters overexpressed during lactation and their role in the transfer of products into the milk, including both beneficial and harmful compounds. Furthermore, additional factors, such as regulation, polymorphisms or drug-drug interactions will be described.

APA, Harvard, Vancouver, ISO, and other styles

9

Aminova, Al'bina, Idris Yumaguzin, Niyaz Subhankulov, and Tatyana Sedykh. "Efficacy of a herbal drug in treating bovine mastitis." Agrarian Bulletin of the 209, no. 06 (July 15, 2021): 34–42. http://dx.doi.org/10.32417/1997-4868-2021-209-06-34-42.

Full text

Abstract:

Abstract. Presently, mastitis is being addressed by biologically active agents of plant origin having a bactericidal, viricidal and immune-modulating effect. In this regard, the study of the Raido drug to treat different types of mastitis in lactating cows is of a certain scientific and practical importance. The aim of the study was to determine the efficacy of the Raido herbal drug against serous and catarrhal mastitis in cows during the lactation period. Research methods. Mastitis was detected according to clinical observations, with the results being confirmed by the express diagnosticum Mastidinum or a quick mastitis test. The blood morphological composition in terms of erythrocyte, leucocyte and haemoglobin content was analyzed on a haematological analyzer. Milk samples were examined bacteriologically for the pathogenic microflora. Results. Treating serous and catarrhal mastitis with the Raido herbal drug increased the level of erythrocytes and haemoglobin in recovering cows, reduced their leucocyte content in the peripheral blood, and somatic cells in milk more than doubled. There were no clinical signs of the disease on the fifth day when serving serous mastitis with 5 or 7 ml of the herbal drug intercisternally. Treating catarrhal mastitis with 10 and 12 ml of the drug using the same administration method produced a similar effect on the sixth day. Thus, the optimal dose for daily interstitial administration of serous mastitis was 5 ml and 10 ml for catarrhal mastitis. A comparison of the therapeutic effects of the phytomedicines Raido and Riposol revealed higher efficacy of the daily Raido use in these dosages. Scientific novelty. For the first time, the optimal dosage of the Raido herbal drug for intercisternal administration to cows with serous and catarrhal mastitis was determined; the therapeutic effect of the Raido herbal remedy was detected; a comparative assessment of the Raido and Riposol herbal remedies' effect in the treatment of serous and catarrhal mastitis was made.

APA, Harvard, Vancouver, ISO, and other styles

10

Mehatre, Dhulappa Dharmaji. "Experimental Evaluation of Karpasa Beeja (Gossypium herbacum Linn.) With special reference to its Galactagogue Effect." International Journal of Ayurvedic Medicine 11, no. 1 (March 24, 2020): 35–43. http://dx.doi.org/10.47552/ijam.v11i1.1337.

Full text

Abstract:

Increased urbanization created lack of authentic and genuine drug for the management of ailments of human beings; similarly the urbanization has fashioned myths in society that lactation and feedings of the babies leads to loss of beauty, along with this stress, strain and modern style of living affects the milk production in human being. Galactogouges are most used and prescribed drugs in the medical practice. As per Ayurveda galactogouges are termed as stanyajanana dravya, which increase the milk production. Karpasa beeja (Gossypium herbacum Linn) belongs to Malvaceae family is medium sized tree consists madhura rasa (sweet taste), sheeta veerya (cold potency), and madhura vipaka (under goes sweet metabolism). It acts as vata, pitta shamaka, kapha vardhaka, and stanyajanana (increases lactation). The Karpasa beeja was subjected for morphological and physico-chemical evaluation according to the parameters explained in Ayurveda Pharmacopeia of India and galactogogue activity was carried out for 15 days by using 24 Albino rats divided into four groups i.e. two trial groups (Churna and Extract of Karpas Beeja), one standard group (Shatavari churna) and one control group (Normal saline water). The drug shows presence of carbohydrate, proteins, sterols, reducing sugar, tannins, flavonoids, alkaloids. The drug in the form of churna and 90% Ethyl alcohol extract shows similar effects with known standard drug Shatavari (Asparagus racemosa).

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Lactation – Drug effects"

1

Briggs, Gerald G. Drugs in lactation. 2nd ed. Baltimore: Williams & Wilkins, 1997.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

1935-, Freeman Roger K., and Yaffe Sumner J. 1923-, eds. Drugs in Pregnancy and Lactation. 7th ed. Baltimore: Lippincott Williams & Wilkins, 2005.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Program, Motherisk, ed. Cancer in pregnancy and lactation: The Motherisk guide. Cambridge, UK: Cambridge University Press, 2011.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Briggs, Gerald G. Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk. 3rd ed. Baltimore: Williams & Wilkins, 1990.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

1935-, Freeman Roger K., and Yaffe Sumner J. 1923-, eds. Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk. 6th ed. Philadelphia, Pa: Lippincott Williams & Wilkins, 2002.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

G, Briggs Gerald, Nageotte Michael P, and American Society of Health-System Pharmacists., eds. Diseases, complications, and drug therapy in obstetrics: A guide for clinicians. Bethesda, Md: American Society of Health-System Pharmacists, 2009.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Briggs, Gerald G. Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk on CD-ROM. [Philadelphia, Pa.]: Lippincott, Williams & Wilkins, 1999.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Hale, Thomas Wright. Medications and mothers' milk. Amarillo, TX: Pharmasoft Medical Pub., 2004.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Hale, Thomas Wright. Medications and mothers' milk. Amarillo, TX: Pharmasoft Medical Publishing, 2002.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

Medications and mothers' milk. 4th ed. Amarillo, Tex: Pharmasoft Medical Publishing, 1995.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Lactation – Drug effects"

1

Wilson, John T., R. Don Brown, Iain J. Smith, and James L. Hinson. "Potentially Toxic Effects of Drug and Toxins in Human Breast Milk." In Human Lactation 3, 301–15. Boston, MA: Springer US, 1987. http://dx.doi.org/10.1007/978-1-4899-0837-7_34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Pangtey, Ghan Shyam, and Niharika Agarwal. "Nonsteroidal Anti-inflammatory Drug Use During Pregnancy and Lactation: Effects on Mother and Child." In Women's Health in Autoimmune Diseases, 215–19. Singapore: Springer Singapore, 2020. http://dx.doi.org/10.1007/978-981-15-0114-2_21.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Østensen, M. E. "Safety of Non-Steroidal Anti-Inflammatory Drugs during Pregnancy and Lactation." In Side Effects of Anti-Inflammatory Drugs IV, 55–65. Dordrecht: Springer Netherlands, 1997. http://dx.doi.org/10.1007/978-94-011-5394-2_7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Ainsworth, Sean. "Drug prescribing and drug administration." In Neonatal Formulary, edited by Sean Ainsworth, 2–52. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780198840787.003.0001.

Full text

Abstract:

Safe prescribing during pregnancy and lactation requires an understanding not only of the effects of a drug on the mother but also on the fetus or infant. Many mothers are prescribed at least one medicine with the potential for harmful effects on either the fetus or infant. Few drugs are deemed safe and effective during these periods and most medications in pregnancy are used ‘off label’. Neonates, too, are ‘therapeutic orphans’—most drugs used in the neonatal intensive care unit (NICU) are not approved by regulatory authorities and are, therefore, used ‘off label’. As such there is greater onus on the prescriber to make sure that they understand the consequences of their prescription. This first section covers important aspects of prescribing, medicines storage, and administration. It also explains how medicines safe at other ages cause toxicity, not just from the drug itself but also from the excipients that are sometimes required.

APA, Harvard, Vancouver, ISO, and other styles

5

Verlohren, Stefan. "Drugs during pregnancy and breastfeeding." In ESC CardioMed, edited by Vera Zagrosek-Regitz, 2876–82. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198784906.003.0696.

Full text

Abstract:

Pregnant women with pre-existing cardiovascular disease may require drug therapy during their pregnancy and lactation period. There are no uniform recommendations for selection of medications, dosing, and timing of treatment. Possible adverse or teratogenic effects of the drugs on the fetus must be weighed against the maternal indication of drug treatment. This chapter gives an overview of medical treatment options for cardiovascular diseases in pregnancy. Furthermore, sources of evidence which can be used for risk classification of drugs applied during pregnancy are shown.

APA, Harvard, Vancouver, ISO, and other styles

6

Bergantin, Maria Rhona G., and Sandra V. Navarra. "Infection in a pregnant patient on immunosuppressive treatment." In Practical management of the pregnant patient with rheumatic disease, edited by Karen Schreiber, Eliza Chakravarty, and Monika Østensen, 95–108. Oxford University Press, 2021. http://dx.doi.org/10.1093/med/9780198845096.003.0009.

Full text

Abstract:

Patients on immunosuppressive therapies have greater susceptibility to a broad range of infections and pose a special challenge during pregnancy and lactation. Anti-microbials must be given with due consideration to side-effects, drug-drug interactions, and importantly safety to the growing foetus and the breastfeeding baby. This chapter further elucidates on modes of transmission and prevention of some infections which can significantly impact materno-foetal outcomes. Systemic autoimmune diseases must be kept under good control during pregnancy since untreated disease carries its own risks to both the mother and the developing foetus. Whilst infections are an important complication of immunosuppressive drugs used for many autoimmune rheumatic diseases, their clinical manifestations may be masked or absent among immunosuppressed individuals.

APA, Harvard, Vancouver, ISO, and other styles

7

Jara, Antonio J., Mona Alsaedy, Alberto F. Alcolea, Miguel Zamora, and Antonio F. Gómez-Skarmeta. "Intelligent System to Quality Assurance in Drugs Delivery." In Quality Assurance in Healthcare Service Delivery, Nursing and Personalized Medicine, 187–202. IGI Global, 2012. http://dx.doi.org/10.4018/978-1-61350-120-7.ch010.

Full text

Abstract:

Improving quality assurance and providing effective healthcare are some of the most important aims of information and communication technologies (ICT). This chapter presents a novel solution to improve quality assurance in drugs delivery, i.e., reduce clinical errors caused by drug interaction and dose. For that purpose, we have proposed an innovative system based on Internet of things for the drugs identification. Internet of things (IoT) is one of the latest advances in ICT, providing a global connectivity and management of sensors, devices, users, and information. Our contribution is a solution to examine drug related problems based on IoT technologies, i.e. smart phones and Web, to support ubiquitous access, 6LoWPAN technology to support ubiquitous data collection of patients, sensors and hospitals, and RFID/NFC to support global identification. These technologies offer a wide range of applications in healthcare, which improves the quality of services, reduces mistakes, and even detects health anomalies from vital signs. This chapter presents how IoT technology is applied in a pharmaceutical system to examine drugs in order to detect Adverse Drug Reactions (ADRs), harmful effects of pharmaceutical excipients, allergies, complications and contraindications related with liver and renal defects, and harmful side effects during pregnancy or lactation. Thereby, the system provides an enhanced approach assisting physicians in clinical decisions and drug prescribing. The solution presented is based on NFC (Near Field Communication), RFID (Radio Frequency Identification), and barcode identification technologies, which have been integrated in common devices such as smart-phones, PDAs, and PCs. In addition, a remote knowledge-based system based ontologies and rules-engine, has been built to define an intelligent drugs checker, which we have defined as Pharmaceutical Intelligent Information System, where the drug identifies collected from the RFID/NFC tag or barcode is checked, in order to detect whether the identified drug is suitable with respect to the patient’s health record.

APA, Harvard, Vancouver, ISO, and other styles

8

Ainsworth, Sean. "Maternal medication and its effect on the baby." In Neonatal Formulary, edited by Sean Ainsworth, 858–942. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780198840787.003.0037.

Full text

Abstract:

All too often the pregnant or breastfeeding mother is told that she cannot receive a drug because the manufacturer has advised against its use. Such information is usually derived from the Summary of Product Characteristics and reflects a lack of information of such use during the early stages of drug development and licensing. These statements are always cautious, seldom very informative, and often merely designed to meet the minimum requirement laid down by the licensing authority. While there are a small number of drugs whose use during pregnancy and lactation is extremely unwise, for most drugs it is more a matter of balancing the advantages and the disadvantages. Information from pregnancy and lactation databases increasingly supplements the information from animal teratogenicity and toxicology studies. Prescribers must consider both disease and drug characteristics when making decisions on medication use during both pregnancy and lactation. They can then use this information to balance the risks of fetal or neonatal exposure against the potential benefits of maternal treatment and the risks of untreated disease. This section allows the reader to quickly look up such risks and, through the references, examine the primary literature to help the mother make an informed choice.

APA, Harvard, Vancouver, ISO, and other styles

9

Neville, Margaret C., and Carol T. Walsh. "Effects of drugs on milk secretion and composition." In Drugs and Human Lactation, 15–46. Elsevier, 1996. http://dx.doi.org/10.1016/b978-044481981-9/50021-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Marshall, Tarnya, Rita Abdulkader, Poonam Sharma, and Alice Malpas. "Antirheumatic drugs in pregnancy and lactation." In Oxford Textbook of Rheumatology, 734–42. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0097_update_004.

Full text

Abstract:

Antirheumatic drugs in pregnancy and lactation are increasingly a common clinical dilemma. With the shift towards early, aggressive control of autoimmune diseases and with the advent of newer therapeutic agents, there is a need to understand the effects of these medicines in pregnancy and lactation, on fertility in both men and women, and on the process of spermatogenesis, in order to understand the risk of teratogenesis. Although there are some limited data available for the use of antirheumatic drugs in pregnancy and lactation, much of our knowledge is derived from animal models and from limited clinical experience in human pregnancy. The balance of therapeutic benefits and risks of harm to mother and fetus should always be carefully considered: it may vary between individuals and should be assessed on a case by case basis. Because of these issues, pregnancy should always be discussed and planned in advance, in part to reduce disease activity prior to conception but also to minimize risk to the fetus. In this chapter we use the available evidence to discuss medicines which are commonly used in the treatment of rheumatological autoimmune diseases, and cover disease-modifying antirheumatic drugs (DMARDS) and biological agents.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!